C. Robert, L. Thomas, I. Bondarenko, O. Day, S. Weber et al., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2543, 2011.
DOI : 10.1056/NEJMoa1104621

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

D. Schadendorf, F. Hodi, C. Robert, J. Weber, K. Margolin et al., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, pp.1889-94, 2015.
DOI : 10.1200/JCO.2014.56.2736

S. Kelderman, B. Heemskerk, H. Van-tinteren, R. Van-den-brom, G. Hospers et al., Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2014.
DOI : 10.1007/s00262-014-1528-9

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel et al., Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.24, issue.6, pp.1697-703, 2013.
DOI : 10.1093/annonc/mdt027

D. Giacomo, A. Danielli, R. Calabro, L. Bertocci, E. Nannicini et al., Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy), Cancer Immunology, Immunotherapy, vol.37, issue.4, pp.467-77, 2011.
DOI : 10.1007/s00262-010-0958-2

A. Martens, K. Wistuba-hamprecht, G. Foppen, M. Yuan, J. Postow et al., Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clinical Cancer Research, vol.22, issue.12, pp.2908-2926, 2016.
DOI : 10.1158/1078-0432.CCR-15-2412
URL : https://hal.archives-ouvertes.fr/inserm-01409624

C. Meyer, L. Cagnon, C. Costa-nunes, P. Baumgaertner, N. Montandon et al., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer Immunology, Immunotherapy, vol.60, issue.10, pp.247-57, 2014.
DOI : 10.1007/s00262-013-1508-5

B. Weide, A. Martens, H. Zelba, C. Stutz, E. Derhovanessian et al., Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells, Clinical Cancer Research, vol.20, issue.6, pp.1601-1610, 2014.
DOI : 10.1158/1078-0432.CCR-13-2508

B. Weide, H. Zelba, E. Derhovanessian, A. Pflugfelder, T. Eigentler et al., Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis, Journal of Clinical Oncology, vol.30, issue.15, pp.1835-1876, 2012.
DOI : 10.1200/JCO.2011.40.2271

H. Braumuller, T. Wieder, E. Brenner, S. Assmann, M. Hahn et al., T-helper-1-cell cytokines drive cancer into senescence, Nature, vol.192, issue.7437, pp.361-366, 2013.
DOI : 10.1038/nature11824

P. Kvistborg, C. Shu, B. Heemskerk, M. Fankhauser, C. Thrue et al., T cell compartment in melanoma patients, OncoImmunology, vol.9, issue.4, pp.409-427, 2012.
DOI : 10.1073/pnas.89.8.3429

W. Holtmeier and D. Kabelitz, Gammadelta T cells link innate and adaptive immune responses, Chem Immunol Allergy, vol.86, pp.151-83, 2005.
DOI : 10.1159/000086659

P. Vantourout and A. Hayday, Six-of-the-best: unique contributions of ???? T cells to immunology, Nature Reviews Immunology, vol.101, issue.2, pp.88-100, 2013.
DOI : 10.1038/nri3384

S. Porcelli, M. Brenner, and H. Band, Biology of the Human gamma T-Cell Receptor, Immunological Reviews, vol.17, issue.2, pp.137-83, 1991.
DOI : 10.1016/0092-8674(89)90861-1

Y. Chien, C. Meyer, and M. Bonneville, T Cells: First Line of Defense and Beyond, Annual Review of Immunology, vol.32, issue.1, pp.121-55, 2014.
DOI : 10.1146/annurev-immunol-032713-120216

K. Wistuba-hamprecht, K. Haehnel, N. Janssen, I. Demuth, and G. Pawelec, Peripheral blood T-cell signatures from high-resolution immune phenotyping of ???? and ???? T-cells in younger and older subjects in the Berlin Aging Study II, Immunity & Ageing, vol.45, issue.1, p.25, 2015.
DOI : 10.1186/s12979-015-0052-x

J. Dechanet, P. Merville, F. Berge, G. Bone-mane, J. Taupin et al., Major Expansion of ???? T Lymphocytes following Cytomegalovirus Infection in Kidney Allograft Recipients, The Journal of Infectious Diseases, vol.179, issue.1, pp.1-8, 1999.
DOI : 10.1086/314568

B. Silva-santos, K. Serre, and H. Norell, ???? T cells in cancer, Nature Reviews Immunology, vol.45, issue.11, pp.683-91, 2015.
DOI : 10.1038/nri3904

A. Hayday, ???? Cells: A Right Time and a Right Place for a Conserved Third Way of Protection, Annual Review of Immunology, vol.18, issue.1, pp.975-1026, 2000.
DOI : 10.1146/annurev.immunol.18.1.975

H. Kobayashi and Y. Tanaka, ???? T Cell Immunotherapy???A Review, Pharmaceuticals, vol.8, issue.1, pp.40-61, 2015.
DOI : 10.3390/ph8010040

H. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori et al., Human T Cell Receptor ???? Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells, The Journal of Experimental Medicine, vol.263, issue.2, pp.163-171, 2003.
DOI : 10.1038/sj.onc.1203002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193814

D. Kabelitz, S. Kalyan, H. Oberg, and D. Wesch, Human V??2 versus non-V??2 ???? T cells in antitumor immunity, OncoImmunology, vol.2, issue.3, p.23304, 2013.
DOI : 10.1084/jem.20102548

M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger et al., ???? T cells for immune therapy of patients with lymphoid malignancies, Blood, vol.102, issue.1, pp.200-206, 2003.
DOI : 10.1182/blood-2002-12-3665

F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia et al., Targeting Human ???? T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer, Cancer Research, vol.67, issue.15, pp.7450-7457, 2007.
DOI : 10.1158/0008-5472.CAN-07-0199

H. Kobayashi, Y. Tanaka, J. Yagi, Y. Osaka, H. Nakazawa et al., Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study, Cancer Immunology, Immunotherapy, vol.173, issue.11, pp.469-76, 2007.
DOI : 10.1007/s00262-006-0199-6

A. Yazdi, K. Morstedt, U. Puchta, K. Ghoreschi, M. Flaig et al., Heterogeneity of T-Cell Clones Infiltrating Primary Malignant Melanomas, Journal of Investigative Dermatology, vol.126, issue.2, pp.393-401, 2006.
DOI : 10.1038/sj.jid.5700082

K. Argentati, F. Re, S. Serresi, M. Tucci, B. Bartozzi et al., Reduced Number and Impaired Function of Circulating ???? T Cells in Patients with Cutaneous Primary Melanoma, Journal of Investigative Dermatology, vol.120, issue.5, pp.829-863, 2003.
DOI : 10.1046/j.1523-1747.2003.12141.x

I. Petrini, S. Pacini, S. Galimberti, M. Taddei, A. Romanini et al., Impaired function of gamma-delta lymphocytes in melanoma patients, European Journal of Clinical Investigation, vol.67, issue.11, pp.1186-94, 2011.
DOI : 10.1111/j.1365-2362.2011.02524.x

J. Campillo, J. Martinez-escribano, A. Minguela, R. Lopez-alvarez, L. Marin et al., Increased Number of Cytotoxic CD3+CD28??? ???? T Cells in Peripheral Blood of Patients with Cutaneous Malignant Melanoma, Dermatology, vol.214, issue.4, pp.283-291, 2007.
DOI : 10.1159/000100878

K. Wistuba-hamprecht, D. Benedetto, S. Schilling, B. Sucker, A. Schadendorf et al., Phenotypic characterization and prognostic impact of circulating ???? and ???? T-cells in metastatic malignant melanoma, International Journal of Cancer, vol.138, issue.3, pp.698-704, 2016.
DOI : 10.1002/ijc.29818

A. Bialasiewicz, J. Ma, and G. Richard, alpha /beta - and gamma /delta TCR+ lymphocyte infiltration in necrotising choroidal melanomas, British Journal of Ophthalmology, vol.83, issue.9, pp.1069-73, 1999.
DOI : 10.1136/bjo.83.9.1069

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

A. Martens, K. Wistuba-hamprecht, J. Yuan, M. Postow, P. Wong et al., Increases in absolute lymphocytes and circulating CD4þ and CD8þ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab, Clin Cancer Res, p.2016
URL : https://hal.archives-ouvertes.fr/inserm-01408937

L. Bertram, A. Bockenhoff, I. Demuth, S. Duzel, R. Eckardt et al., Cohort Profile: The Berlin Aging Study II (BASE-II), International Journal of Epidemiology, vol.43, issue.3, pp.703-715, 2014.
DOI : 10.1093/ije/dyt018

K. Wistuba-hamprecht, G. Pawelec, and E. Derhovanessian, OMIP-020: Phenotypic characterization of human ???? T-cells by multicolor flow cytometry, Cytometry Part A, vol.104, issue.6, pp.522-526, 2014.
DOI : 10.1002/cyto.a.22470

C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins et al., Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009.
DOI : 10.1200/JCO.2009.23.4799
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035

N. Himoudi, D. Morgenstern, M. Yan, B. Vernay, L. Saraiva et al., Human ???? T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells, The Journal of Immunology, vol.188, issue.4, pp.1708-1724, 2012.
DOI : 10.4049/jimmunol.1102654

M. Muto, M. Baghdadi, R. Maekawa, H. Wada, and K. Seino, Myeloid molecular characteristics of human ???? T cells support their acquisition of tumor antigen-presenting capacity, Cancer Immunology, Immunotherapy, vol.107, issue.19, pp.941-950, 2015.
DOI : 10.1007/s00262-015-1700-x

D. Wesch, C. Peters, and G. Siegers, Human Gamma Delta T Regulatory Cells in Cancer: Fact or Fiction?, Frontiers in Immunology, vol.40, issue.10, p.598, 2014.
DOI : 10.1016/j.immuni.2014.03.013

C. Peters, H. Oberg, D. Kabelitz, and D. Wesch, Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells, Cell Mol Life Sci, vol.71, issue.10, 2014.

A. Thedrez, C. Sabourin, J. Gertner, M. Devilder, S. Allain-maillet et al., Self/non-self discrimination by human ???? T cells: simple solutions for a complex issue?, Immunological Reviews, vol.153, issue.1, pp.123-158, 2007.
DOI : 10.1182/blood-2004-01-0331

T. C. , T. Ying, W. Kilian, X. Weili, N. Ma-schwe-zin et al., Vd2þ and a/b T cells show divergent trajectories during human aging Recent advances in gamma/delta T cell biology: new Ligands, new functions, and new Translational perspectives, Oncotarget Front Immunol, vol.6, p.371, 2015.

S. Coffelt, K. Kersten, C. Doornebal, J. Weiden, K. Vrijland et al., IL-17-producing ???? T cells and neutrophils conspire to promote breast cancer metastasis, Nature, vol.224, issue.7556, pp.345-353, 2015.
DOI : 10.1038/nature14282
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475637

P. Wu, D. Wu, C. Ni, J. Ye, W. Chen et al., ????T17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer, Immunity, vol.40, issue.5, pp.785-800, 2014.
DOI : 10.1016/j.immuni.2014.03.013

V. Lafont, F. Sanchez, E. Laprevotte, H. Michaud, L. Gros et al., Plasticity of gammadelta T Cells: impact on the anti-tumor response, Front Immunol, vol.5, p.622, 2014.

M. Iwasaki, Y. Tanaka, H. Kobayashi, K. Murata-hirai, H. Miyabe et al., Expression and function of PD-1 in human ???? T cells that recognize phosphoantigens, European Journal of Immunology, vol.154, issue.2, pp.345-55, 2011.
DOI : 10.1002/eji.201040959

V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-koehler, M. Goebeler et al., Tumor-promoting Versus Tumor-antagonizing Roles of ???? T Cells in Cancer Immunotherapy, Journal of Immunotherapy, vol.35, issue.2, pp.205-218, 2012.
DOI : 10.1097/CJI.0b013e318245bb1e